AbbVie Inc. (ABBV) Q2 FY2026 8-K Filings and Company Events
More for AbbVie: Company index · Financial statements · 10-K and 10-Q summary
PeriodQ2 FY2026
Published
This page digests the material Form 8-K filings AbbVie Inc. (ABBV) has made over roughly the trailing five quarters: earnings releases, management and board changes, capital returns, financing, and governance actions. Each item cites the SEC accession number of the filing it came from. It is current through Q2 FY2026, the period ended 2026-06-30, as reported in the 10-Q filed with the SEC.
Filings that contain financial statements
- Form 8-K filed July 31, 2026 (accession 0001551152-26-000023): Exhibit 99.1 furnishes AbbVie's second-quarter and six-month 2026 GAAP consolidated statements of earnings, key-product revenue tables and GAAP-to-non-GAAP reconciliations for the periods ended June 30, 2026 (with June 30, 2025 comparatives).
- Form 8-K filed April 29, 2026 (accession 0001551152-26-000013): Exhibit 99.1 furnishes the first-quarter 2026 GAAP consolidated statement of earnings, key-product revenue table and reconciliations for the quarter ended March 31, 2026 (with March 31, 2025 comparatives).
- Form 8-K filed February 4, 2026 (accession 0001551152-26-000004): Exhibit 99.1 furnishes the fourth-quarter and full-year 2025 GAAP consolidated statements of earnings, key-product revenue tables and reconciliations for the periods ended December 31, 2025 (with 2024 comparatives).
- Form 8-K filed October 31, 2025 (accession 0001551152-25-000047): Exhibit 99.1 furnishes the third-quarter and nine-month 2025 GAAP consolidated statements of earnings, key-product revenue tables and reconciliations for the periods ended September 30, 2025 (with 2024 comparatives).
Apogee Therapeutics acquisition
- September 3, 2026, AbbVie completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion; Apogee's common stock ceased trading prior to market open the same day. AbbVie said the deal will reduce adjusted diluted EPS by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032, and reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88 (Form 8-K, accession 0001104659-26-104940).
- June 22, 2026, AbbVie and Apogee announced a definitive merger agreement under which AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash (approximately a 49% premium to Apogee's June 18, 2026 closing price), a total equity value of approximately $10.9 billion (implied transaction value of approximately $10.1 billion net of Apogee's estimated cash and marketable securities). The deal adds Apogee's immunology pipeline, led by zumilokibart (APG777, an IL-13 antibody for atopic dermatitis) and APG273 (an IL-13/TSLP combination for asthma). AbbVie said it would fund the transaction with debt, expected the deal to close in the third quarter of 2026, and to be $0.14 dilutive to adjusted diluted EPS in 2026 and approximately $0.46 dilutive in 2027, with accretion beginning in 2032 (Form 8-K, accession 0001104659-26-076067, and Exhibit 99.2 investor presentation).
Debt financing tied to the Apogee acquisition
- August 18, 2026, AbbVie closed an underwritten public offering of $10.0 billion aggregate principal amount of senior notes across nine tranches (floating-rate notes due 2028 and fixed-rate notes due 2028 through 2066), issued under Supplemental Indenture No. 13. AbbVie said the offering was conducted in connection with the Apogee acquisition and that proceeds would fund a portion of the cash consideration for Apogee, with any excess for general corporate purposes (Form 8-K, accession 0001104659-26-098367).
- August 4–5, 2026, AbbVie entered into the underwriting agreement for the notes offering above; expected net proceeds of approximately $9.93 billion, intended to fund a portion of the Apogee cash consideration and reduce commitments under a $10.0 billion 364-day delayed-draw term loan facility entered into in connection with the acquisition (Form 8-K, accession 0001104659-26-091269).
Other capital markets activity
- March 4, 2026, AbbVie closed an underwritten public offering of $8.0 billion aggregate principal amount of senior notes across seven tranches (floating-rate notes due 2028 and fixed-rate notes due 2028 through 2066), issued under Supplemental Indenture No. 12. Net proceeds of approximately $7.95 billion were intended to repay amounts outstanding under a $4.0 billion 364-day delayed-draw term loan facility maturing in May 2026 (of which $2.0 billion was then outstanding) and for general corporate purposes (Form 8-K, accession 0001104659-26-023534; underwriting agreement entered February 24, 2026, accession 0001104659-26-020643).
Earnings and guidance
- July 31, 2026, second-quarter 2026 results. Net revenues were $16.990 billion, up 10.2% reported (9.5% operational). GAAP diluted EPS was $2.03 (up 290.4%) and adjusted diluted EPS was $3.65 (up 22.9%), including a $0.17 per-share unfavorable impact from acquired IPR&D and milestones expense. Immunology net revenues were $8.786 billion (Skyrizi $5.505 billion, Rinvoq $2.525 billion, Humira $756 million). AbbVie updated its full-year 2026 adjusted diluted EPS guidance to $13.87–$14.07 (from $13.91–$14.11), reflecting the anticipated $0.14 per-share dilution from the pending Apogee acquisition partly offset by $0.10 of overperformance (Form 8-K, accession 0001551152-26-000023).
- July 6, 2026, AbbVie disclosed preliminary second-quarter 2026 acquired IPR&D and milestones expense of $291 million pre-tax (an unfavorable $0.17 per-share impact to both GAAP and adjusted EPS), updating full-year 2026 adjusted diluted EPS guidance to $13.91–$14.11 and second-quarter guidance to $3.57–$3.61 (Form 8-K, accession 0001551152-26-000021).
- April 29, 2026, first-quarter 2026 results. Net revenues were $15.002 billion, up 12.4% reported (10.3% operational). GAAP diluted EPS was $0.39 (down 45.8%) and adjusted diluted EPS was $2.65 (up 7.7%), including a $0.41 per-share unfavorable impact from acquired IPR&D and milestones expense. Immunology net revenues were $7.290 billion (Skyrizi $4.483 billion, Rinvoq $2.119 billion, Humira $688 million). AbbVie raised full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28 from $13.96–$14.16 (Form 8-K, accession 0001551152-26-000013).
- April 3, 2026, AbbVie disclosed preliminary first-quarter 2026 acquired IPR&D and milestones expense of $744 million pre-tax (an unfavorable $0.41 per-share impact), updating full-year 2026 adjusted diluted EPS guidance to $13.96–$14.16 (Form 8-K, accession 0001551152-26-000011).
- February 4, 2026, fourth-quarter and full-year 2025 results. Full-year net revenues were $61.160 billion, up 8.6% reported. Full-year GAAP diluted EPS was $2.36 (down 1.3%) and adjusted diluted EPS was $10.00 (down 1.2%), including a $2.76 per-share unfavorable impact from 2025 acquired IPR&D and milestones expense. Fourth-quarter net revenues were $16.618 billion, up 10.0%; GAAP diluted EPS was $1.02 and adjusted diluted EPS was $2.71. AbbVie issued initial full-year 2026 adjusted diluted EPS guidance of $14.37–$14.57, excluding any impact from future acquired IPR&D and milestones expense (Form 8-K, accession 0001551152-26-000004). The same filing disclosed a voluntary agreement with the U.S. administration under which AbbVie will provide lower Medicaid prices and expanded direct-to-patient affordability programs, commit $100 billion to U.S. R&D and capital investment (including manufacturing) over the next decade, and receive a three-year exemption from tariffs and future pricing mandates; it also disclosed a definitive agreement with West Pharmaceutical Services for AbbVie to acquire a device-manufacturing facility in Tempe, Arizona, and associated intellectual property.
- January 7, 2026, AbbVie disclosed preliminary fourth-quarter 2025 acquired IPR&D and milestones expense of approximately $1.3 billion pre-tax (an unfavorable $0.71 per-share impact), updating full-year 2025 adjusted diluted EPS guidance to $9.90–$9.94 (Form 8-K, accession 0001551152-26-000002).
- October 31, 2025, third-quarter 2025 results. Net revenues were $15.776 billion, up 9.1% reported. GAAP diluted EPS was $0.10 (down 88.6%) and adjusted diluted EPS was $1.86 (down 38.0%), including a $1.50 per-share unfavorable impact from acquired IPR&D and milestones expense. AbbVie raised full-year 2025 adjusted diluted EPS guidance to $10.61–$10.65 from $10.38–$10.58. The board also declared a 5.5% increase in the quarterly cash dividend, to $1.73 per share from $1.64 per share, beginning with the dividend payable February 17, 2026, to shareholders of record January 16, 2026 (Form 8-K, accession 0001551152-25-000047). The same release disclosed that AbbVie had completed its acquisition of Capstan Therapeutics (an in vivo CAR-T/lipid-nanoparticle platform for autoimmune disease) and completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, a Phase 2 psychedelic compound for major depressive disorder.
- October 3, 2025, AbbVie disclosed preliminary third-quarter 2025 acquired IPR&D and milestones expense of approximately $2.7 billion pre-tax (an unfavorable $1.50 per-share impact), updating full-year 2025 adjusted diluted EPS guidance to $10.38–$10.58 (Form 8-K, accession 0001551152-25-000043).
Governance
- May 8, 2026, At AbbVie's annual meeting of stockholders, all four Class II director nominees were elected, Ernst & Young LLP's appointment as auditor was ratified, and the say-on-pay advisory vote passed. A management proposal to eliminate supermajority voting requirements from the certificate of incorporation was not approved, and a stockholder proposal to require an independent board chair was not approved (Form 8-K, accession 0001104659-26-059484).
West Pharmaceutical Services device-facility acquisition
- July 2026, AbbVie's acquisition of West Pharmaceutical Services' device-manufacturing facility in Tempe, Arizona, and associated intellectual property, for which AbbVie disclosed a definitive agreement on February 4, 2026 (Form 8-K, accession 0001551152-26-000004), closed. AbbVie disclosed no purchase price. The closing is disclosed only in the Form 10-Q for the quarter ended June 30, 2026 (accession 0001551152-26-000026), MD&A "Recent Events"; no 8-K covers the closing.
FAQ · AbbVie 8-K filings and events
What has AbbVie Inc. (ABBV) reported in its recent 8-K filings?
Form 8-K filed July 31, 2026 (accession 0001551152-26-000023): Exhibit 99.1 furnishes AbbVie's second-quarter and six-month 2026 GAAP consolidated statements of earnings, key-product revenue tables and GAAP-to-non-GAAP reconciliations for the periods ended June 30, 2026 (with June 30, 2025 comparatives). Form 8-K filed April 29, 2026 (accession 0001551152-26-000013): Exhibit 99.1 furnishes the first-quarter 2026 GAAP consolidated statement of earnings, key-product revenue table and reconciliations for the quarter ended March 31, 2026 (with March 31, 2025 comparatives).
When does AbbVie Inc. (ABBV) next file with the SEC?
AbbVie Inc. (ABBV) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from AbbVie Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001551152-26-000026.
Related companies
How this page was built
This page was built from 16 of AbbVie Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from news coverage, analyst commentary or another website. Their accession numbers are cited inline, so any statement here can be traced to the filing it came from and checked against sec.gov.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from AbbVie Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.